Acamprosate Suppresses Ethanol-Induced Place Preference in Mice With Ethanol Physical Dependence

Kazuhiro Kurokawa1, Koji Mizuno1, Masahiro Shibasaki1, Masaya Higashioka2, Michiko Oka2, Masaaki Hirouchi2, and Seitaro Ohkuma1,*

1Department of Pharmacology, Kawasaki Medical School, Matsushima 577, Kurashiki 701-0192, Japan
2Research Laboratories, Nippon Shinyaku Co., Ltd., 14, Nishinosho-monguchi-cho, Kisshoin, Minami-Ku, Kyoto 601-8550, Japan

Received March 19, 2013; Accepted June 6, 2013

Abstract. The present study investigated the effect of acamprosate on ethanol (EtOH)-induced place preference in mice with EtOH physical dependence. The expression of EtOH (2 g/kg, intraperitoneally)-induced place preference in mice without EtOH treatment before the experiment was dose-dependently suppressed by acamprosate. The levels of protein kinase A (PKA) and phospho-cAMP response element binding protein (p-CREB) in the limbic forebrain after EtOH-conditioning in naïve mice was unchanged. Furthermore, mice on the 4th day of withdrawal from continuous EtOH vapor inhalation for 9 days showed transient and significant enhancement of EtOH (1 g/kg, intraperitoneally)-induced place preference, which was significantly suppressed by acamprosate (300 mg/kg, oral administration; p.o., once a day) administered daily for 3 days after withdrawal from EtOH inhalation and during EtOH-conditioning. PKA and p-CREB proteins in the limbic forebrain of EtOH-conditioned mice on 4th day of withdrawal from continuous EtOH inhalation for 9 days significantly increased, which were completely abolished by acamprosate. These findings suggest that the signal transduction pathway via the PKA–p-CREB pathway in the limbic forebrain may be functionally related to the development of sensitization of EtOH-induced place preference and provide a possible molecular basis for the pharmacological effect of acamprosate to prevent or reduce the relapse of alcohol dependence.

Keywords: ethanol, acamprosate, alcohol dependence, phospho-cAMP response element binding protein (p-CREB), conditioned place preference

Introduction

The mesolimbic dopaminergic system projects its neuronal fibers predominantly to the nucleus accumbens and prefrontal cortex from the ventral tegmental area. A number of studies have reported the pathophysiological roles of this neuronal system in mediating the reinforcing and rewarding effects of psychostimulants including cocaine and ethanol (EtOH) (1, 2). EtOH increases the firing rate of dopamine neurons in the ventral tegmental area (3) and the extracellular dopamine levels in the nucleus accumbens (4, 5). Based on those observations, the mesolimbic dopaminergic system is supposed to play an important role in the development and expression of EtOH-induced place preference. In addition, our recent reports demonstrate that the conditioning for 8 days with EtOH (EtOH administration: 1 time / 2 days) induces significant place preference (6), and that mice on the 3 days after the withdrawal from continuous EtOH vapor inhalation for 9 days show enhanced EtOH-induced place preference (7).

Accumulating evidence suggests that changes of transcription factors, such as the cyclic-AMP response element binding protein (CREB), in the nucleus accum-
bems participate in the mechanism of the development of dependence on drugs of abuse (8–10). In addition, EtOH alters the increases in phosphorylation of CREB (p-CREB) and p-CREB appears to modulate EtOH self-administration and EtOH-drinking (11, 12). These changes of p-CREB level and cAMP response element (CRE)-mediated gene expression occur in several brain regions in response to drugs of abuse (13). We demonstrated in the recent report that p-CREB and PKA were up-regulated in the lower midbrain including the ventral tegmental area of mice with EtOH physical dependence (14). However, little is known about the changes of p-CREB and PKA in the nucleus accumbens of mice on the development of EtOH-induced place preference.

Because of the structural similarity of acamprosate to γ-aminobutyric acid (GABA) and taurine, studies focused on clarifying the mechanisms of action for the effect of acamprosate on functional interaction with inhibitory receptors, especially GABA A receptors (15). On the other hand, current investigations suggest that a possible action site of acamprosate may be N-methyl-D-aspartate (NMDA) receptors (16). Furthermore, several investigations have demonstrated that in the nucleus accumbens, acamprosate blocks glutamate increase during EtOH withdrawal (17) and elevates extracellular dopamine level; the latter action of acamprosate is mediated via activating glycine receptors (18). However, the precise molecular mechanism of action of acamprosate on EtOH-induced place preference remains unclear.

The clinical efficacy of acamprosate has been evaluated in clinical trials (19, 20), whereas recent studies carried out in the United States and Australia suggest that acamprosate is not superior to placebo (21–23). On the other hand, previous reports using experimental animals have demonstrated that intraperitoneal (i.p.) administration of acamprosate inhibits the development of EtOH-induced place preference in mice (24). In addition, acamprosate has been reported to reduce EtOH consumption in animal models (25–27). Therefore, as the first goal of this study, we attempted to confirm whether oral administration of acamprosate at a dose almost equivalent to that used in the clinical field modifies EtOH-induced conditioned place preference, especially in mice treated with continuous EtOH vapor inhalation prior to measuring EtOH-induced conditioned place preference. The second goal is to examine whether PKA and p-CREB protein expression, which is facilitated by dopamine, increase in the limbic forebrain of mice with enhanced EtOH-induced place preference, because few data on the biochemical mechanism of action of acamprosate on EtOH-induced place preference in mice are available at present.

Materials and Methods

Reagents and antibodies
EtOH was obtained from Wako Pure Chemicals (Osaka). Acamprosate was a kind gift from Merck Santé S.A.S. (Lyon, France). Protease-inhibitor cocktail was obtained from Roche Diagnostics (Indianapolis, IN, USA). Antibodies against CREB (rabbit polyclonal anti-CREB, #9197), phosphor-CREB (Ser133) (rabbit polyclonal anti-p-CREB, #4276), and PKARI-α (rabbit polyclonal anti-PKA, #5675) were purchased from Cell Signaling Technology, Inc. (Boston, MA, USA). Mouse anti-β-actin (sc-47778) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Horseradish peroxidase–conjugated goat anti-rabbit IgG and goat anti-mouse IgG were the products of Southern Biotechnology Associates, Inc. (Birmingham, AL, USA). EtOH was dissolved in saline when injected i.p. Acamprosate was dissolved in distilled water. The other agents used here were locally available and of analytical grade.

Animals
Male ddY mice (8-week-old: 33–37 g; Japan SLC, Inc., Hamamatsu) were housed in a room maintained at 22°C ± 1°C, and 55% humidity with a 12-h light/dark cycle (light on 8:00 A.M. to 8:00 P.M.) for 1 week prior to the experiments. Mice were group-housed 4 per cage. Food and water were available ad libitum.

The study was conducted in compliance with the Law for Humane Treatment and Management of Animals of Japan (Law No. 105, October 1, 1973, as revised on June 1, 2006).

Procedure for EtOH vapor inhalation
EtOH vapor inhalation in mice was carried out by the previous method (14, 28, 29) with a minor modification. Mice were housed in the cage for 1–2 weeks before the beginning of the EtOH vapor inhalation. Mice with initial body weight of 40 g were continuously exposed to EtOH vapor (concentrations of 11 mg/L) or air in a chamber with free access to food and drinking water for 9 days. Mice received an i.p. loading dose of 2.0 g/kg EtOH and pyrazole (68 mg/kg) at the beginning of EtOH vapor inhalation. During continuous inhalation of EtOH vapor, mice were injected i.p. with pyrazole (68 mg/kg), an inhibitor of alcohol dehydrogenase, daily at 10:00 A.M. to stabilize the blood EtOH level. The blood EtOH levels in mice were approximately 2.00 mg/ml during EtOH vapor inhalation (30). Animals exposed to air instead of EtOH vapor with concomitant administration of pyrazole were used as the control. Mice were removed from the chamber at the end of the EtOH exposure (10th day) and thereafter were not injected with pyrazole.
Acamprosate (3, 30, 300 mg/kg) was orally administered at 11:00 A.M. during the withdrawal (treated on the 10th, 11th, and 12th days of the experiment) from EtOH vapor exposure for 9 days.

**Place conditioning**

Place conditioning was examined using mice with 3 different EtOH treatment schedules as described below. 1) Mice were conditioned with EtOH for 8 days (4 sessions) and then administered a single dose of acamprosate 1 h before post-conditioning test (Fig. 1A).

2) Mice continuously inhaled EtOH vapor for 9 days, then housed without treatment with acamprosate for 3 days, and finally EtOH conditioning (4 days: 2 sessions) with daily acamprosate administration (Fig. 3A).

3) Mice continuously inhaled EtOH vapor for 9 days, then housed with daily treatment with acamprosate for 3 days, and finally received EtOH conditioning (4 days: 2 sessions) with daily acamprosate administration (Figs. 4A, 5A, and 6A).

The apparatus consisting of a shuttle box that was made of acrylic resin boards and divided into 2 equal-sized compartments as previously reported (6, 7) was used for place conditioning studies. One compartment was black with a smooth floor and the other was white with a textured floor to create equally inviting compartments. The conditioning place preference schedule consisted of three phases (pre-conditioning test, conditioning, and post-conditioning test).

The pre-conditioning test: Before the pre-conditioning test, mice were placed on the border of both compartments and then the amount of time that each mouse spent in each compartment during the 900-s session was recorded automatically using an infrared beam sensor (BS-CPP-MS; BrainSienceIdea, Co., Ltd., Osaka). The compartment in which the mouse spent a longer time was defined as the preferred compartment and the other compartment was defined as the non-preferred one. Mice spending more than 600 s in one compartment were excluded from the experiment. The remaining mice were divided into 2 groups according to place preference, that is, 1 group consisted of mice preferring the black compartment and the other consisted of those preferring the white compartment. The baseline preference in each test group for the black and white compartments was approximately 50%. With such biased assignment, mice were conditioned in their non-preferred compartment [drug (EtOH)-paired compartment].

Conditioning sessions: Conditioning sessions followed the pre-conditioning test. During this test, mice administered EtOH were conditioned in the non-preferred compartment [drug (EtOH)-paired compartment] and those administered saline were placed in the preferred compartment (saline-paired compartment). That is, the day after the pre-conditioning test, mice were placed in the drug (EtOH)-paired compartment for 30 min immediately after i.p. injection of EtOH or placed in the saline-paired compartment for 30 min immediately after i.p. injection of saline, and on an alternative day, mice were conditioned in the saline-paired compartment for 30 min with saline injection or in the drug (EtOH)-paired compartment for 30 min with EtOH treatment, respectively. The experiment of Fig. 1B showed that mice received for 4 EtOH (2 mg/kg)-paired sessions and 4 saline-paired sessions, respectively. Such a cycle of conditioning was carried out for 8 days. On the other hand, in the experiments in Figs. 3: B – C, 4: B – C, 5: B – C, and 6: B – C, mice received for 2 EtOH (1 mg/kg)-paired sessions and 2 saline-paired sessions, respectively. Such a cycle of conditioning was carried out for 4 days. Moreover, acamprosate at one dose (3, 30, 300 mg/kg) was orally administered everyday 1 h before i.p. treatment with EtOH (1 mg/kg) or saline during EtOH conditioning and for 3 days after withdrawal from continuous EtOH inhalation.

Post-conditioning test: On the day after the final conditioning session, a post-conditioning test identical to the pre-conditioning test was carried out for 900 s. The preference for the drug-paired place was expressed as the mean difference between the duration spent in it during the pre- and post-conditioning tests. For the experiment shown in Fig. 1B, acamprosate (3, 30, 300 mg/kg, p.o.) was administered 1 h before the post-conditioning test.

The schedule of place preference conditioning and the time to administer acamprosate are presented in Figs. 1A, 3A, 4A, 5A, and 6A.

**Tissue dissection and preparation of samples for western blotting**

Immediately after the post-conditioning test, the limbic forebrain (including the nucleus accumbens and olfactory tubercle) was dissected from the decapitated animal on an ice-cold glass plate and homogenized with ice-cold lysis buffer (pH 7.5) containing 10 mM Tris-HCl, 150 mM NaCl, 0.5 mM EDTA, 10 mM NaF, and 0.5% Triton X-100 with a protease-inhibitor cocktail.

The homogenate was centrifuged at 1,000 × g for 60 min at 4°C. The supernatants were used as the cytosol fractions for measuring the immunoreactivity of CREB and p-CREB, and the resultant supernatant was further centrifuged at 100,000 × g for 60 min at 4°C. The supernatants were used as the cytosol fractions for measuring the immunoreactivity of PKA.
**Immunoblotting**

Protein concentration in the samples was assayed by the method of Lowry et al. (31). After electrophoresis (applied proteins for PKA, 15 µg/lane; for CREB and p-CREB, 20 µg/lane) using a 3% – 8% Tris-acetate gel (size, 8 × 8 cm; thickness, 1.0 mm; Invitrogen, Carlsbad, CA, USA) at 150 V for 60 min, proteins separated on the gel were transferred to a nitrocellulose filter with a wet-type transblotter (90 V, 60 min). For immunoblot detection of separated proteins, the membrane was incubated overnight at 4°C with primary antibodies against PKA (rabbit polyclonal anti-PKA, 1:1000), CREB (rabbit polyclonal anti-CREB, 1:1000), p-CREB (rabbit polyclonal anti-p-CREB, 1:1000), and β-actin (mouse monoclonal anti-β-actin; 1:3000) diluted in phosphate-buffered saline (PBS) containing 3% nonfat dried milk, further incubated for 2 h at room temperature with horseradish peroxidase-conjugated goat anti-rabbit IgG and goat anti-mouse IgG diluted 1:5000 in PBS containing 3% nonfat dried milk, and finally washed 6 times (each washing for 10 min) with PBS containing 0.1% Tween 20. The separated proteins were thereafter detected by chemiluminescence detection reagents (GE Healthcare UK, Ltd., Amersham Place, Little Chalfont, UK) and were scanned with Image Quant LAS 4000 mini (GE Healthcare UK).

**Statistical analyses**

Each of the data was represented as the mean ± S.E.M. Statistical analysis was carried out using Prism 5 (GraphPad, Inc., San Diego, CA, USA). The data obtained from all experiments except for the protein levels of PKA and p-CREB in Fig. 2: A and B were analyzed with Tukey’s multiple comparison test. The statistical differences between saline- and EtOH-conditioned groups in Fig. 2: A and B were analyzed with Student’s t-test. Statistical analysis of the data on dose-dependency was evaluated with the test for linear trend. A level of probability of 0.05 or less was evaluated to be significant.

**Results**

**Effect of acamprosate on expression of EtOH-induced place preference**

In order to investigate the effect of acamprosate on the expression of EtOH-induced place preference, acamprosate was administrated 1 h before the post-conditioning. EtOH (2 g/kg, i.p.) produced significant place preference ($P < 0.001$), which was suppressed by acamprosate in a dose-dependent manner ($P < 0.05$, test for linear trend; $P < 0.001$, Fig. 1B). However, acamprosate (300 mg/kg, p.o.) alone showed neither significant place preference nor place aversion in mice.

**Changes in protein levels of PKA and p-CREB in the limbic forebrain of mice during conditioned place preference to EtOH**

Using mice receiving the same experimental schedule presented in Fig. 1A, the changes in the protein levels of PKA and p-CREB in the limbic forebrain were examined by western blot analysis. PKA and p-CREB in the limbic forebrain showed no changes by EtOH conditioning (Fig. 2: B and C, respectively).

**Effect of acamprosate on change of EtOH-induced place preference after continuous EtOH vapor inhalation**

In the first series of the experiments, acamprosate was administered only during EtOH-conditioning, but not treated with this drug during the 3 days after EtOH inhalation. Control mice (not treated with EtOH vapor for 9 days) conditioned by two-paired EtOH (1.0 g/kg)
sessions showed no significant place preference compared with saline conditioning mice (Fig. 3B). On the other hand, in mice after 3 days of the withdrawal from EtOH inhalation for 9 days, EtOH-conditioning with two-paired EtOH (1.0 g/kg) sessions significantly increased place preference compared with saline-conditioned mice ($P < 0.001$, Fig. 3C). Under such conditions, the increase in the EtOH-induced place preference was not significantly inhibited by acamprosate administered only during EtOH-conditioning (Fig. 3C).

In the second series of the experiments, acamprosate was administered during both 3 days after withdrawal from EtOH inhalation for 9 days, EtOH-conditioning with two-paired EtOH (1.0 g/kg) sessions significantly increased place preference compared with saline-conditioned mice ($P < 0.001$, Fig. 3C). Under such conditions, the increase in the EtOH-induced place preference was not significantly inhibited by acamprosate administered only during EtOH-conditioning (Fig. 3C).

The present study demonstrates significant inhibitory effects of acamprosate orally administered on the expression of and the development of EtOH-induced place preference; the latter effect was observed in mice on the 3 days after withdrawal from continuous EtOH vapor inhalation.

Although the present study demonstrates the inhibitory potential of oral acamprosate on the expression of EtOH-induced place preference, previous reports have also demonstrated that the i.p. administration of acamprosate inhibits the development of EtOH-induced place preference in DBA mice (24). On the other hand, the protein levels of PKA and p-CREB in the limbic forebrain were unchanged in mice showing EtOH-induced place preference. Similarly, data have been reported that feeding of EtOH Liber-DeCarli liquid diet for 15 days caused no changes of PKA and p-CREB in the rat.
Kurokawa et al. (32). It is therefore considered to be reasonable that such short-term treatment with EtOH on conditioning may be inadequate to induce the increase of the expression of these proteins or that the time for measuring these proteins is too early to express the increase of these proteins in the brain.

Our recent study showed that mice after 3 days of withdrawal from continuous EtOH vapor inhalation for 9 days showed transient enhancement of EtOH (1 g/kg)-induced place preference (7), suggesting that the sensitization of EtOH-induced place preference as animal behaviors occurs in mice under these experimental conditions. Similarly, behavioral sensitization of locomotor activity to EtOH has been reported and this change of locomotor activity tends to be long-lasting (33). Furthermore, several reports have shown that the behavioral changes observed in animals after withdrawal from chronic EtOH exposure are considered to be due to adaptive changes in neurotransmission systems including glutamatergic and GABAergic transmission systems (34, 35). These experimental data suggest that the alternations of these neuronal transmission systems on and during withdrawal from EtOH physical dependence may develop sensitization to EtOH-induced place preference.

Recent studies suggest that acamprosate acts as an NMDA-receptor modulator (16, 36). Moreover, chronic EtOH treatment or withdrawal from it up-regulates NMDA-receptor function in the brain (37 – 39), showing that NMDA receptors may play an important role in EtOH physical dependence and withdrawal from EtOH dependence. These data also suggest that the significant suppression of increase in EtOH-induced place preference by acamprosate after the withdrawal from continuous EtOH exposure may be mediated via the modulating action of acamprosate on NMDA-receptor function.

The interesting findings in present study are that acamprosate shows significant inhibitory potential to the increase of PKA and p-CREB in the limbic forebrain of mice after 3 days of the withdrawal from continuous EtOH vapor exposure as well as to increased EtOH-conditioned place preference. A previous study suggests that activation of the PKA-regulated signaling pathway in the nucleus accumbens is one of potentially important mechanisms that may contribute to behavioral changes occurring across the addiction cycle (40). In addition, inhibition of PKA activity in the nucleus accumbens has
Fig. 4. Effect of acamprosate (administered during withdrawal from EtOH vapor for 3 days plus EtOH conditioning for 4 days) on changes of EtOH-induced place preference after continuous EtOH vapor inhalation. A) Schedule of the experiment. B and C) Control mice (B, not treated with EtOH vapor inhalation) and mice with continuous EtOH vapor inhalation for 9 days (C). Oral acamprosate (3, 30, and 300 mg/kg) administration was carried out daily during withdrawal from EtOH vapor inhalation plus EtOH-conditioning. During the EtOH-conditioning period, acamprosate (3, 30, and 300 mg/kg) was orally administered 1 h before i.p. treatment with saline (SAL) and EtOH (1 g/kg). For EtOH conditioning, mice were treated i.p. with SAL or EtOH two times every other day for 4 days (during the conditioning session: 2 days for EtOH, 2 days for SAL) during conditioning period. Each column represents the mean ± S.E.M. of 13 – 15 animals. N.S., not significant. ***$P < 0.001$ (Tukey’s multiple comparison test).

Fig. 5. Effect of acamprosate (administered during withdrawal from EtOH vapor for 3 days plus EtOH conditioning for 4 days) on enhanced expression of PKA in the limbic forebrain of mice after EtOH conditioning. A) Schedule of the experiment. B) Control mice were not treated with EtOH vapor inhalation. C) Mice inhaled EtOH vapor for 9 days. After mice inhaled EtOH vapor for 9 days, acamprosate (300 mg/kg) was orally administered daily for 3 days after the withdrawal from continuous EtOH inhalation and 4 days during EtOH conditioning. During the conditioning period, acamprosate (300 mg/kg) was orally administered 1 h before i.p. treatment with saline (SAL) and EtOH (1 g/kg). For measuring EtOH-induced place preference, mice were treated i.p. with SAL or EtOH two times every other day for 4 days (during the conditioning session: 2 days for EtOH, 2 days for SAL) during the conditioning period. The cytosol fractions used for measuring PKA were prepared 24 h after the last conditioning with EtOH or saline. Each column represents the mean ± S.E.M. of 4 mice. N.S., not significant. *$P < 0.05$ (Tukey’s multiple comparison test).
been reported to attenuate amphetamine-induced place conditioning (41). These previous and present data suggest that the activation of PKA play an important role in EtOH-conditioned place preference.

Previous investigations demonstrated the up-regulation of NMDA receptors after EtOH exposure increased NMDA receptor–mediated calcium flux in cortical neurons (37, 42). Furthermore, activation of NMDA receptors increases CREB phosphorylation (43) and the number of p-CREB-immunoreactive cells in the shell of the nucleus accumbens in mice with behavioral sensitization after repeated treatment with EtOH (44). The present study demonstrated that, in the limbic forebrain of EtOH-conditioned mice after 3 days of the withdrawal from continuous EtOH inhalation, increase of p-CREB protein expression was observed, which was abolished by the pretreatment with acamprosate. In addition, CREB can be also activated via phosphorylation by PKA. These results therefore suggest that the changes of p-CREB may be involved in the development of the sensitization of EtOH-induced place preference. However, exact mechanisms of regulatory effects of acamprosate on these neurochemical changes possibly involved in sensitization of EtOH-induced place preference remain to be elucidated.

In conclusion, the present study demonstrated that orally administered acamprosate inhibited the expression of EtOH-induced place preference. The increase in EtOH-induced place preference observed in mice after 3 days of withdrawal from EtOH physical dependence was inhibited by acamprosate. The increased expression of PKA and p-CREB in the limbic forebrain of EtOH-conditioned mice 3 days after withdrawal from EtOH physical dependence were also inhibited by the acamprosate. These findings suggest that the signal transduction pathway mediated through the PKA–p-CREB pathway in the limbic forebrain may be functionally related to the development of sensitization of EtOH-induced place preference and provide a possible molecular basis for the pharmacological effect of acamprosate to prevent or reduce the relapse of alcohol dependence.

**Conflicts of Interest**

The author has no conflict of interest to disclose with respect to this study.

**References**

Acamprosate and Ethanol Dependence


38 Hoffman PL, Tabakoff B. The role of the NMDA receptor in ethanol withdrawal. EXS. 1994;71:61–70.


44 Nona CN, Guirguis S, Nobrega JN. Susceptibility to ethanol sensitization is differentially associated with changes in pCREB, trkB and BDNF mRNA expression in the mouse brain. Behav Brain Res. 2013;242:25–33.